Cambrex News and Resources

Cambrex, a global CDMO, announced its partnership with Lilly Catalyze360-ExploR&D, the innovation arm of Eli Lilly and Company, to provide development services for Lilly’s biotech collaborators. The collaboration will accelerate early-stage drug development through Cambrex’s expertise in drug substance, drug

Cambrex, a global contract development and manufacturing organisation (CDMO), has announced the opening of a new cGMP stability storage facility in Durham, North Carolina. The facility, operated by its subsidiary Q1 Scientific, expands the company’s capability to provide temperature-controlled storage

Cambrex, a contract development and manufacturing organisation, is set to expand its stability storage business, Q1 Scientific, by opening a new facility in Durham, North Carolina. This facility, scheduled to be operational by the end of 2024, will feature advanced

Cambrex, a contract development and manufacturing organisation (CDMO), is nearing the completion of its ambitious 5-year, $100-million-dollar investment strategy with the completion of the project expected by the end of 2024. The investment strategy, which was originally planned to span